These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 16621179

  • 41. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages.
    Rodríguez-Sosa M, Rivera-Montoya I, Espinoza A, Romero-Grijalva M, López-Flores R, González J, Terrazas LI.
    Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349
    [Abstract] [Full Text] [Related]

  • 42. [Novel vaccines against M. tuberculosis].
    Okada M.
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [Abstract] [Full Text] [Related]

  • 43. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK, Naskar K, De T.
    Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
    [Abstract] [Full Text] [Related]

  • 44. Protection of C3HeB/FeJ mice against Leishmania amazonensis challenge after previous Leishmania major infection.
    Vanloubbeeck Y, Jones DE.
    Am J Trop Med Hyg; 2004 Oct; 71(4):407-11. PubMed ID: 15516635
    [Abstract] [Full Text] [Related]

  • 45. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.
    Jaafari MR, Badiee A, Khamesipour A, Samiei A, Soroush D, Kheiri MT, Barkhordari F, McMaster WR, Mahboudi F.
    Vaccine; 2007 Aug 10; 25(32):6107-17. PubMed ID: 17629372
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Vaccination with the divergent portion of the protein histone H2B of Leishmania protects susceptible BALB/c mice against a virulent challenge with Leishmania major.
    Chenik M, Louzir H, Ksontini H, Dilou A, Abdmouleh I, Dellagi K.
    Vaccine; 2006 Mar 24; 24(14):2521-9. PubMed ID: 16417957
    [Abstract] [Full Text] [Related]

  • 48. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis.
    Rafati S, Zahedifard F, Nazgouee F.
    Vaccine; 2006 Mar 15; 24(12):2169-75. PubMed ID: 16325969
    [Abstract] [Full Text] [Related]

  • 49. Exacerbation of Leishmania (Viannia) shawi infection in BALB/c mice after immunization with soluble antigen from amastigote forms.
    Passero LF, Da Costa Bordon ML, De Carvalho AK, Martins LM, Corbett CE, Laurenti MD.
    APMIS; 2010 Dec 15; 118(12):973-81. PubMed ID: 21091779
    [Abstract] [Full Text] [Related]

  • 50. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
    Yamakami K, Akao S, Sato M, Nitta Y, Miyazaki J, Tadakuma T.
    Parasitol Int; 2001 Jul 15; 50(2):81-91. PubMed ID: 11438430
    [Abstract] [Full Text] [Related]

  • 51. Development of a leishmaniasis vaccine: the importance of MPL.
    Reed SG, Coler RN, Campos-Neto A.
    Expert Rev Vaccines; 2003 Apr 15; 2(2):239-52. PubMed ID: 12899575
    [Abstract] [Full Text] [Related]

  • 52. Intranasal vaccination with extracellular serine proteases of Leishmania amazonensis confers protective immunity to BALB/c mice against infection.
    de Matos Guedes HL, da Silva Costa BL, Chaves SP, de Oliveira Gomes DC, Nosanchuk JD, De Simone SG, Rossi-Bergmann B.
    Parasit Vectors; 2014 Sep 19; 7():448. PubMed ID: 25239157
    [Abstract] [Full Text] [Related]

  • 53. Peripheral expression of LACK-mRNA induced by intranasal vaccination with PCI-NEO-LACK defines the protection duration against murine visceral leishmaniasis.
    De Oliveira Gomes DC, Schwedersky RP, Barbosa De-Melo LD, Da Silva Costa Souza BL, De Matos Guedes HL, Lopes UG, Rossi-Bergmann B.
    Parasitology; 2012 Oct 19; 139(12):1562-9. PubMed ID: 23036534
    [Abstract] [Full Text] [Related]

  • 54. Leishmania amazonensis: humoral response to amastigote excreted-antigens in murine leishmaniasis.
    Hernández-Chinea C.
    Exp Parasitol; 2007 Aug 19; 116(4):492-6. PubMed ID: 17349625
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
    Rostamian M, Niknam HM.
    Mol Immunol; 2017 Nov 19; 91():202-208. PubMed ID: 28963929
    [Abstract] [Full Text] [Related]

  • 60. Evaluation of vaccinal effectiveness of preparations containing membrane antigens of Leishmania (L.) amazonensis in experimental cutaneous leishmaniasis model.
    Ribeiro JG, Ferreira AS, Macedo SRA, Rossi NRDLP, da Silva MCP, Guerra RNM, de Barros NB, Nicolete R.
    Int Immunopharmacol; 2017 Jun 19; 47():227-230. PubMed ID: 28433944
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.